REINVENTING PAIN RELIEF
CHANGING THE WAY WE MANAGE PAIN
VIRPAX’s proprietary pipeline is well positioned to meet the unmet needs in a multi-billion dollar market.
EpoladermTM will be the only metered-dose topical Diclofenac Epolamine spray film indicated for osteoarthritis of the knee.
VIRPAX will also introduce its proprietary ProbudurTM, a single injectable liposomal gel local anesthetic for postoperative pain management. Probudur will be the only liposomal gel bupivacaine with 96 hours of postoperative pain control; 24 hours longer than any other liposomal bupivacaine.
The FDA indicated that if Probudur can meet its clinical end points in two or more clinical trials, the results of those studies could be reflected in a labeling claim.
NES100 is being studied to manage moderate to severe acute and chronic pain without the concerns of dependence, respiratory depression, and tolerance compared to morphine.